UNSPSC 51422343: Dexamethasone tebutate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C28H39FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8IPA7Z9N7Y, chemically known as 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 21-(3,3-dimethylbutyrate), but more generally known as dexamethasone tebutate, which bears US NIH Compound Identifier 20055086. European Medicines Agency schedules Dexamethasone tebutate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01618MIG.

Most nations, for tariff and trade purposes, schedule dexamethasone tebutate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE TEBUTATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)CC(C)(C)C)O)C)O)F)C.

UNSPSC 51422343 Dexamethasone tebutate is a Commodity code that nominally covers a specific corticosteroid pharmaceutical, but the recent state and local opportunities tagged under it do not reflect procurement of that agent. Seminole County, Florida's IFB 60459723LAS solicits naloxone and drug deactivation systems for community health delivery—opioid-reversal medication and harm-reduction equipment unrelated to dexamethasone tebutate. The Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription programs and pharmacy benefit design, a strategic sourcing question rather than a product buy. The code shows a significant mismatch between its nominal scope and recent state and local activity. No recent opportunities demonstrate procurement of dexamethasone tebutate itself.

The geographic activity visible in the available records spans Florida and Texas, but both opportunities are exploratory or tangential to the code's stated product scope. Seminole County's IFB, posted June 30, 2026 with a response due July 26, 2023, targets 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendors to include shipping and maintain workers' compensation and commercial general liability insurance. The Texas HHS RFI, posted April 3, 2026 with the same response date, seeks vendor capabilities for direct manufacturer contracting and negotiated net-pricing models but does not specify a formal procurement vehicle or budget. The code exhibits little relevant recent activity for dexamethasone tebutate procurement at the state and local level.